CY1121825T1 - Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου - Google Patents

Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου

Info

Publication number
CY1121825T1
CY1121825T1 CY20191100760T CY191100760T CY1121825T1 CY 1121825 T1 CY1121825 T1 CY 1121825T1 CY 20191100760 T CY20191100760 T CY 20191100760T CY 191100760 T CY191100760 T CY 191100760T CY 1121825 T1 CY1121825 T1 CY 1121825T1
Authority
CY
Cyprus
Prior art keywords
phosphoinositide
zinc
kinase inhibitor
binding module
kinase
Prior art date
Application number
CY20191100760T
Other languages
English (en)
Inventor
Cai Xiong
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Original Assignee
Curis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis, Inc. filed Critical Curis, Inc.
Publication of CY1121825T1 publication Critical patent/CY1121825T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση παρέχει μια ένωση του Χημικού Τύπου I και μια μέθοδο για την παρασκευή της, φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις και τη χρήση τέτοιων ενώσεων στη θεραπευτική αντιμετώπιση σχετιζόμενων με φωσφοϊνοσιτιδίου 3-κινάση παθήσεων και διαταραχών όπως ο καρκίνος. Η τρέχουσα αίτηση αναφέρεται περαιτέρω στη θεραπευτική αντιμετώπιση σχετιζόμενων με ιστονική απακετυλάση διαταραχών και παθήσεων που σχετίζονται τόσο με ιστονική απακετυλάση όσο και με φωσφοϊνοσιτιδίου 3-κινάση.
CY20191100760T 2011-04-01 2019-07-17 Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου CY1121825T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14
EP12764605.7A EP2694075B1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
CY1121825T1 true CY1121825T1 (el) 2020-07-31

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100683T CY1117785T1 (el) 2011-04-01 2016-07-14 Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
CY20191100760T CY1121825T1 (el) 2011-04-01 2019-07-17 Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100683T CY1117785T1 (el) 2011-04-01 2016-07-14 Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου

Country Status (30)

Country Link
US (7) US8710219B2 (el)
EP (2) EP3111938B1 (el)
JP (3) JP6242331B2 (el)
KR (2) KR101902325B1 (el)
CN (2) CN103582483B (el)
AU (1) AU2012236367B2 (el)
BR (1) BR112013025340B1 (el)
CA (1) CA2830822C (el)
CL (1) CL2013002823A1 (el)
CY (2) CY1117785T1 (el)
DK (2) DK2694075T3 (el)
EA (1) EA022434B9 (el)
ES (2) ES2577982T3 (el)
HK (1) HK1194969A1 (el)
HR (2) HRP20160545T1 (el)
HU (2) HUE028910T2 (el)
IL (2) IL228588A (el)
LT (1) LT3111938T (el)
ME (2) ME03523B (el)
MX (1) MX340577B (el)
PE (1) PE20141382A1 (el)
PL (2) PL2694075T3 (el)
PT (2) PT3111938T (el)
RS (2) RS54903B1 (el)
SG (2) SG193563A1 (el)
SI (2) SI3111938T1 (el)
SM (1) SMT201600179B (el)
TW (1) TWI571469B (el)
WO (1) WO2012135571A1 (el)
ZA (2) ZA201307082B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI558710B (zh) 2009-01-08 2016-11-21 古利斯股份有限公司 具有鋅連接部位的磷酸肌醇3-激酶抑制劑
HUE028910T2 (en) 2011-04-01 2017-01-30 Curis Inc Phosphonoinoside-3-kinase inhibitor with zinc-binding radical
AU2012339640B2 (en) 2011-11-14 2017-01-05 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
AU2016250972B2 (en) * 2015-04-21 2019-01-17 Chengdu Zenitar Biomedical Technology Co., Ltd. Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
AU2017301012B2 (en) * 2016-07-19 2020-07-09 National Institute Of Plant Genome Research Novel protein against fungal pathogens
CN109923117A (zh) * 2016-11-02 2019-06-21 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
AU2018360845B2 (en) * 2017-11-06 2024-05-02 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
EP3849554A4 (en) 2018-09-11 2022-06-01 Curis, Inc. POLYTHERAPY WITH A PHOSPHOINONOSITIDE 3-KINASE INHIBITOR HAVING A ZINC-BINDING METAL
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1485348B1 (en) 2002-03-13 2008-06-11 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
CN100445276C (zh) 2002-03-13 2008-12-24 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
US7767679B2 (en) 2002-03-13 2010-08-03 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
EA007272B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н. В. Новые ингибиторы гистондеацетилазы
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
KR101074462B1 (ko) 2003-01-29 2011-10-18 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 화합물 및 그 용도
CN101010298A (zh) * 2004-04-05 2007-08-01 默克Hdac研究有限责任公司 组蛋白脱乙酰酶抑制剂前药
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
WO2006122926A1 (en) 2005-05-18 2006-11-23 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
US7888360B2 (en) 2006-01-19 2011-02-15 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CN101370790B (zh) 2006-01-19 2015-10-21 詹森药业有限公司 作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
DK2024372T3 (da) 2006-04-26 2010-09-20 Hoffmann La Roche Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor
JP5546240B2 (ja) * 2006-04-26 2014-07-09 ジェネンテック, インコーポレイテッド 医薬化合物
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
JP2010502743A (ja) 2006-09-11 2010-01-28 キュリス,インコーポレイテッド 抗増殖薬剤としての多機能性低分子
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
SG174774A1 (en) 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
KR101312993B1 (ko) 2006-10-28 2013-11-25 엔비보 파마슈티칼즈, 인코퍼레이티드 히스톤 데아세틸라아제의 억제제
MY180595A (en) * 2006-12-07 2020-12-03 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
MX2009005925A (es) * 2006-12-07 2009-08-12 Genentech Inc Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso.
BRPI0807812A2 (pt) 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
CA2680398A1 (en) 2007-03-20 2008-09-25 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
ES2537352T3 (es) * 2007-09-12 2015-06-05 Genentech, Inc. Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009058895A1 (en) 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
TWI558710B (zh) * 2009-01-08 2016-11-21 古利斯股份有限公司 具有鋅連接部位的磷酸肌醇3-激酶抑制劑
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille Pd−1抗体およびpd−l1抗体ならびにその使用
WO2010105008A2 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
WO2011054620A1 (en) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
CN102970868A (zh) * 2010-04-16 2013-03-13 柯瑞斯公司 具有k-ras突变的癌症的治疗
HUE028910T2 (en) * 2011-04-01 2017-01-30 Curis Inc Phosphonoinoside-3-kinase inhibitor with zinc-binding radical
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
EP3313443B9 (en) 2015-06-25 2023-10-04 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN109923117A (zh) * 2016-11-02 2019-06-21 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗

Also Published As

Publication number Publication date
US11135205B2 (en) 2021-10-05
KR20140023333A (ko) 2014-02-26
NZ615586A (en) 2015-02-27
BR112013025340B1 (pt) 2021-12-21
MX2013011132A (es) 2014-03-12
CL2013002823A1 (es) 2014-04-11
JP6275784B2 (ja) 2018-02-07
HRP20191091T1 (hr) 2019-09-20
EP2694075B1 (en) 2016-04-27
IL248597A0 (en) 2016-12-29
MX340577B (es) 2016-07-13
US9249156B2 (en) 2016-02-02
ZA201406167B (en) 2015-03-25
PL3111938T3 (pl) 2019-09-30
CN105461736B (zh) 2018-06-12
US20160185796A1 (en) 2016-06-30
RS54903B1 (sr) 2016-10-31
ES2577982T3 (es) 2016-07-19
US10111864B2 (en) 2018-10-30
KR20180108848A (ko) 2018-10-04
EP2694075A1 (en) 2014-02-12
SG10201602569RA (en) 2016-05-30
CN103582483B (zh) 2016-02-17
TWI571469B (zh) 2017-02-21
TW201247678A (en) 2012-12-01
JP2014509653A (ja) 2014-04-21
EP3111938B1 (en) 2019-05-08
IL228588A0 (en) 2013-12-31
EA022434B1 (ru) 2015-12-30
JP2016188255A (ja) 2016-11-04
CA2830822C (en) 2018-10-02
PT2694075T (pt) 2016-07-11
SI3111938T1 (sl) 2019-08-30
LT3111938T (lt) 2019-06-25
HRP20160545T1 (hr) 2016-06-17
CY1117785T1 (el) 2017-05-17
PT3111938T (pt) 2019-07-10
US20140243330A1 (en) 2014-08-28
DK3111938T3 (da) 2019-07-01
EA022434B9 (ru) 2016-02-29
US10543197B2 (en) 2020-01-28
CN105461736A (zh) 2016-04-06
BR112013025340A2 (pt) 2016-12-13
US20200215039A1 (en) 2020-07-09
US20130090335A1 (en) 2013-04-11
IL228588A (en) 2016-11-30
PL2694075T3 (pl) 2016-09-30
SG193563A1 (en) 2013-11-29
ZA201307082B (en) 2015-04-29
US11654136B2 (en) 2023-05-23
EP2694075A4 (en) 2014-10-01
SMT201600179B (it) 2016-08-31
IL248597B (en) 2018-04-30
US20190091211A1 (en) 2019-03-28
US9657032B2 (en) 2017-05-23
AU2012236367A1 (en) 2013-04-18
AU2012236367B2 (en) 2014-10-09
CA2830822A1 (en) 2012-10-04
HK1194969A1 (zh) 2014-10-31
ME03523B (me) 2020-04-20
US8710219B2 (en) 2014-04-29
RS59219B1 (sr) 2019-10-31
JP2018052987A (ja) 2018-04-05
WO2012135571A1 (en) 2012-10-04
ME02451B (me) 2016-09-20
NZ705039A (en) 2016-03-31
US20220168284A1 (en) 2022-06-02
PE20141382A1 (es) 2014-11-04
EA201301114A1 (ru) 2014-04-30
SI2694075T1 (sl) 2016-07-29
EP3111938A1 (en) 2017-01-04
CN103582483A (zh) 2014-02-12
JP6242331B2 (ja) 2017-12-06
KR101902325B1 (ko) 2018-09-28
US20170304279A1 (en) 2017-10-26
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
DK2694075T3 (en) 2016-08-01
ES2733128T3 (es) 2019-11-27

Similar Documents

Publication Publication Date Title
CY1121825T1 (el) Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
CY1124068T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1120866T1 (el) Παρεμποδιστες dna-pk
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
BR112017019453A2 (pt) compostos e composições de alfa-cinamida como inibidores de hdac8
BR112016011024A2 (pt) Composto, composição farmacêutica, e, usos dos mesmos
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
UA110338C2 (en) Chemical compounds
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
EA201500426A1 (ru) Производные пирролотриазинона в качестве ингибиторов pi3k
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201591498A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201270728A1 (ru) Пуриновые соединения